MISSED OUT ON THE LATEST CLINICAL GUIDELINE ANNOUNCEMENTS?

No problem, we’ve got you covered! Here’s a list to all guidelines and FDA approvals that were published last month. 

CLINICAL GUIDELINES

IDSA
Treatment of ExtendedSpectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTRP. aeruginosa)

WHO
Abortion Care

ACG
Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period

ACS
Spine Injury Best Practices

AAOS
Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants Up to Six Months of Age

AVF/AVLS/SVM
Lymphedema Diagnosis and Treatment

SNMMI
Palliative Nuclear Medicine Therapies of Painful Bone Metastases

ASCRS
Perioperative Evaluation and Management of Frailty Among Older Adults Undergoing Colorectal Surgery

AAOS
Prevention of Surgical Site Infection After Extremity Trauma

ACG
Diagnosis and Management of Barrett’s Esophagus

SCAI
Best Practices for Clinical Proctoring of New Technologies and Techniques

WHO
Maternal and Fetal Assessment Update: Imaging Ultrasound Before 24 Weeks of Pregnancy

ACR
Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

ACR
Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

ACR
Management of Kawasaki Disease

AAN
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis

EXCLUSIVE AHA/ACC, AGA, ASCO, ACR GUIDELINES AND MANY MORE!

Search, bookmark, add notes and create your personal clinical guideline library with your digital copy or one of our society and specialty subscription bundles.   

SEE GUIDELINE BUNDLES

FDA APPROVALS

Mar. 1, 2022       Vonjo
Treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

Mar. 11, 2022     Lynparza
Adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

Mar. 14, 2022      Adlarity
Treatment for patients with mild, moderate, or severe dementia of the Alzheimer’s type.

Mar. 16, 2022     Rinvoq
Treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Mar. 18, 2022     Opdualag
Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Mar. 18, 2022      Ztalmy
Treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older.

Mar. 21, 2022      Keytruda
For Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation.

Mar. 23, 2022      Pluvicto
Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Mar. 23, 2022      Locametz
Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; for selection of patients with metastatic prostate cancer for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.

Mar. 23, 2022      Locametz
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; for selection of patients with metastatic prostate cancer for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.

Mar. 23, 2022      Xelstrym
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for adults and pediatric patients 6 years and older.

Mar. 23, 2022      Xelstrym
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for adults and pediatric patients 6 years and older.

Mar. 29, 2022      Finteplam
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged 2 years and older.

Copyright © 2022 Guideline Central, All rights reserved.